News – Page 960 – Endpoints News

CRISPR Therapeutics treats first patient with gene editing tech; Amicus nabs 'breakthrough' status for Pompe drug

7 years ago

Danaher hands a distressed GE $21B+ for biopharma business that made $3B last year

7 years ago

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

7 years ago

AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

7 years ago

Unfazed by recent cardio setbacks, Novartis takes another PhIII challenge head-on with Akcea drug

7 years ago

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

7 years ago

Roche joins the M&A game, buying gene therapy pioneer Spark for $4.3B

7 years ago

Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant ...

7 years ago

Who’s in line for the next big mega-merger? Morningstar handicaps the odds among the top players

7 years ago

Days after Indivior launches authorized Suboxone generic, Mylan offers its copycat; In crowded CGRP market, Alder ...

7 years ago

AbbVie hands Voyager a mega-billions gene therapy deal, with $310M in near-term cash

7 years ago

EMA opens consultation on guideline for advanced therapies in clinical trials

7 years ago

BioMarin CEO JJ Bienaimé is planning for a blockbuster future in the gene therapy biz: to the tune of $10B to $15B a ...

7 years ago

Pfizer spinout woos Otsuka vet Raymond Sanchez to lead CNS pipeline work; Joe Anderson returns to Arix helm

7 years ago

Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug

7 years ago

So you just got a BTD for your top drug? Don't be surprised to see the enthusiasm fizzle fast among investors

7 years ago

Narcan maker Opiant shelves bulimia program after mid-stage flop

7 years ago

Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote

7 years ago

Dear Bernie: Catalyst CEO McEnany defends his $375,000 price tag on an old drug once offered for free

7 years ago

Allogene blueprints a new manufacturing complex for next-gen CAR-T; Inovio spins out neoantigen upstart with $10.5M A ...

7 years ago

Ramaswamy's rare-disease offshoot Enzyvant poaches Alexion exec Rachelle Jacques to replace Alvin Shih at the helm

7 years ago

Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead

7 years ago

Merck's Roger Perlmutter pays $300M to scoop up a battered Immune Design for its I/O work

7 years ago

MPM adds $408M for its next big wave of biotech startups — and oncology still dominates the menu

7 years ago

First page Previous page 957 958 959960961 962 963 Next page Last page